POLA-R-CHP

Phase 2Small molecule

POLA-R-CHP is one of 122 small molecule programs targeting DLBCL - Diffuse Large B Cell Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

121

Competitors

Pipeline

Status by Indication[3][1]

Indication

DLBCL - Diffuse Large B Cell LymphomaNot yet recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

First-Line TreatmentRecruiting

Phase IBNot yet recruiting

DLBCL - Diffuse Large B Cell LymphomaPhase 2

Not yet recruiting

Diffuse Large B-Cell LymphomaPreclinical

Active, not recruiting

First-Line TreatmentPhase 2

Recruiting

Phase IBPhase 2

Not yet recruiting

Competition

Competitive Landscape

109 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Rituxan

Adriamycin

38 3

Oncovin

Eli Lilly

Phase 3

33 4

Polivy

Roche

Phase 3

20 5

Gazyva

Roche

Phase 3

18 6

Oncovin

Eli Lilly

Phase 3

18 7

Gemzar

Johnson & Johnson

Phase 3

18 8

Adriamycin

Pfizer

Phase 3

18 9

Eloxatin

Teva

Phase 3

16 10

Cytoxan

BBaxter Healthcare Corporation

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Recruiting

Diffuse Large B-Cell Lymphoma

NCT07070648

Q4 2029

Phase 2Recruiting

First-Line Treatment

NCT06743945

Q1 2031

Phase 1/2Not yet recruiting

Phase IB

NCT07398638

Q4 2031

Phase 2Not yet recruiting

DLBCL - Diffuse Large B Cell Lymphoma

NCT07677813

Clinical

Trials by Indication[1]

Phase IB1 trial

Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II Study

Not yet recruiting·SSun Yat-sen University·Phase 1/2·NCT07398638·122 enrolled

Diffuse Large B-Cell Lymphoma1 trial

Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Recruiting·FFudan University··NCT07070648·300 enrolled

First-line Treatment1 trial

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

Recruiting·FFudan University·Phase 2·NCT06743945·20 enrolled

DLBCL - Diffuse Large B Cell Lymphoma1 trial

Efficacy and Safety of Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma: a Single-center, Single-arm, Prospective Study

Not yet recruiting·OOu Bai, MD/PHD·Phase 2·NCT07677813·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for POLA-R-CHP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — POLA-R-CHP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for POLA-R-CHP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFudan University

POLA-R-CHP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q4 2029

Q1 2031

Q4 2031

Trials by Indication[1]

Phase IB1 trial

Diffuse Large B-Cell Lymphoma1 trial

First-line Treatment1 trial

DLBCL - Diffuse Large B Cell Lymphoma1 trial

References

Drug Info

Quick Facts

Related News